Literature DB >> 11454720

Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway.

J Yang1, K Fizazi, S Peleg, C R Sikes, A K Raymond, N Jamal, M Hu, M Olive, L A Martinez, C G Wood, C J Logothetis, G Karsenty, N M Navone.   

Abstract

Metastases from prostatic adenocarcinoma (prostate cancer) are characterized by their predilection for bone and typical osteoblastic features. An in vitro model of bone metastases from prostate cancer was developed using a bicompartment coculture system of mouse osteoblasts and human prostate cancer cells. In this model, the bone-derived prostate cancer cell lines MDA PCa 2a and MDA PCa 2b induced a specific and reproducible increase in osteoblast proliferation. Moreover, these cells were able to induce osteoblast differentiation, as assessed by increased alkaline phosphatase activity, Osteocalcin expression, and calcified matrix formation. This osteoblastic reaction was confirmed in vivo by intrafemoral injection of MDA PCa 2b cells into severe combined immunodeficiency disease mice. In contrast, the highly undifferentiated, bone-derived human prostate cancer cell line PC3 did not produce an osteoblastic reaction in vitro and induced osteolytic lesions in vivo. The osteoblast differentiation induced by MDA PCa 2b cells was associated with up-regulation of the osteoblast-specific transcriptor factor Cbfa1. Moreover, treatment of osteoblasts with conditioned medium obtained from MDA PCa 2b cells resulted in up-regulation of Cbfa1 and Osteocalcin expression. In support of the differentiation studies, a microarray analysis showed that primary mouse osteoblasts grown in the presence of MDA PCa 2b cells showed a shift in the pattern of gene expression with an increase in mRNA-encoding Procollagen type I and Osteopontin and a decrease in mRNA-encoding proteins associated with myoblast differentiation, namely myoglobin and myosin light-chain 2. Taken together, these findings suggest that the bone-derived prostate cancer cells MDA PCa 2a and MDA PCa 2b promote differentiation of osteoblast precursors to an osteoblastic phenotype through a Cbfa1-dependent pathway. These results also established that soluble factors produced by prostate cancer cells can induce expression of osteoblast-specific genes. This in vitro model provides a valuable system to isolate molecules secreted by prostate cancer cells that favor osteoblast differentiation. Moreover, it allows to screen for therapeutic agents blocking the osteoblast response to prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11454720

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

1.  Mouse models for studying prostate cancer bone metastasis.

Authors:  Jinlu Dai; Janine Hensel; Ning Wang; Marianna Kruithof-de Julio; Yusuke Shiozawa
Journal:  Bonekey Rep       Date:  2016-02-17

2.  Osteoblast-derived sphingosine 1-phosphate to induce proliferation and confer resistance to therapeutics to bone metastasis-derived prostate cancer cells.

Authors:  Leyre Brizuela; Claire Martin; Pauline Jeannot; Isabelle Ader; Cécile Gstalder; Guillaume Andrieu; Magalie Bocquet; Jean-Michel Laffosse; Anne Gomez-Brouchet; Bernard Malavaud; Roger A Sabbadini; Olivier Cuvillier
Journal:  Mol Oncol       Date:  2014-04-13       Impact factor: 6.603

3.  p62/SQSTM1 is required for cell survival of apoptosis-resistant bone metastatic prostate cancer cell lines.

Authors:  Megan A Chang; Micaela Morgado; Curtis R Warren; Cimona V Hinton; Mary C Farach-Carson; Nikki A Delk
Journal:  Prostate       Date:  2013-09-30       Impact factor: 4.104

4.  Canine prostate cancer cell line (Probasco) produces osteoblastic metastases in vivo.

Authors:  Jessica K Simmons; Wessel P Dirksen; Blake E Hildreth; Carlee Dorr; Christina Williams; Rachael Thomas; Matthew Breen; Ramiro E Toribio; Thomas J Rosol
Journal:  Prostate       Date:  2014-07-07       Impact factor: 4.104

Review 5.  The role of epithelial plasticity in prostate cancer dissemination and treatment resistance.

Authors:  Rhonda L Bitting; Daneen Schaeffer; Jason A Somarelli; Mariano A Garcia-Blanco; Andrew J Armstrong
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

6.  Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature.

Authors:  Khalid A Mohamedali; Zhi Gang Li; Michael W Starbuck; Xinhai Wan; Jun Yang; Sehoon Kim; Wendy Zhang; Michael G Rosenblum; Nora M Navone
Journal:  Clin Cancer Res       Date:  2011-02-22       Impact factor: 12.531

7.  Canine prostatic cancer cell line (LuMa) with osteoblastic bone metastasis.

Authors:  Said M Elshafae; Wessel P Dirksen; Aylin Alasonyalilar-Demirer; Justin Breitbach; Shiyu Yuan; Noriko Kantake; Wachiraphan Supsavhad; Bardes B Hassan; Zayed Attia; Lucas B Alstadt; Thomas J Rosol
Journal:  Prostate       Date:  2020-04-29       Impact factor: 4.104

8.  Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors.

Authors:  Jami Mandelin; Marina Cardó-Vila; Wouter H P Driessen; Paul Mathew; Nora M Navone; Sue-Hwa Lin; Christopher J Logothetis; Anna Cecilia Rietz; Andrey S Dobroff; Bettina Proneth; Richard L Sidman; Renata Pasqualini; Wadih Arap
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-11       Impact factor: 11.205

Review 9.  Prostate cancer regulatory networks.

Authors:  Dario C Altieri; Lucia R Languino; Jane B Lian; Janet L Stein; Irwin Leav; Andre J van Wijnen; Zhong Jiang; Gary S Stein
Journal:  J Cell Biochem       Date:  2009-08-01       Impact factor: 4.429

10.  A 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions.

Authors:  Eliza L S Fong; Xinhai Wan; Jun Yang; Micaela Morgado; Antonios G Mikos; Daniel A Harrington; Nora M Navone; Mary C Farach-Carson
Journal:  Biomaterials       Date:  2015-11-09       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.